Prospects and challenges of CAR-T cell therapy combined with ICIs

Yufan Lv; Xinyu Luo; Zhuoyi Xie; Jieya Qiu; Jinsai Yang; Yuqi Deng; Rou Long; Guiyang Tang; Chaohui Zhang; Jianhong Zuo

doi:10.3389/fonc.2024.1368732

Prospects and challenges of CAR-T cell therapy combined with ICIs

Front Oncol. 2024 Mar 20:14:1368732. doi: 10.3389/fonc.2024.1368732. eCollection 2024.

Authors

Yufan Lv¹, Xinyu Luo¹, Zhuoyi Xie², Jieya Qiu², Jinsai Yang³, Yuqi Deng², Rou Long², Guiyang Tang², Chaohui Zhang¹, Jianhong Zuo^{1

2

3

4}

Affiliations

¹ The Affiliated Nanhua Hospital, Hengyang Medical School, University of South China, Hengyang, China.
² Transformation Research Lab, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
³ Computer Institute, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
⁴ The Third Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China.

Abstract

Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.

Keywords: CAR-T cells; combination therapy; immune checkpoints; immunotherapy; solid tumors.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work is supported by the Key Research Program from the Science and Technology Department of Ningxia Hui Autonomous Region, China (2019BFH02012); the Key Research Program of Hunan Health Committee (20201909); the Program of Hengyang science and Technology Bureau (2017-1, 2020-67); Clinical Research of 4310 Program (20224310NHYCG12).